Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

Trial Profile

A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Autoimmune disorders; Breast cancer; Cancer; Cancer pain; Cardiovascular disorders; Myocardial infarction; Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Kancera
  • Most Recent Events

    • 06 Mar 2020 Results fom the final part of this study published in the Kancera Media Release
    • 05 Feb 2020 According to an Kancera media release, the company has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567.The company estimates that the results of the study may become available in March 2020.
    • 04 Dec 2019 Results of in-depth immunological analysis of blood samples from healthy subjects of this study presented in a Kancera media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top